不同剂量米非司酮治疗子宫腺肌病的疗效比较研究  

Comparative study of different doses of mifepristone in patients with uterine adenomyosis

作　　者：陈钢[1] 蒋秋丽 

机构地区：[1]陕西省汉中市中心医院妇科,陕西汉中723000

出　　处：《安徽医药》2012年第11期1677-1678,共2页Anhui Medical and Pharmaceutical Journal

摘　　要：目的探讨不同剂量米非司酮治疗子宫腺肌病的疗效及安全性。方法将106例子宫腺肌病患者随机分为A组(54例)和B组(52例),分别给予米非司酮6.25 mg.d-1、12.5 mg.d-1,每天1次,疗程为3个月。观察两组的临床疗效、子宫大小和CA125水平变化及不良反应情况。结果治疗后,A组的总有效率为94.4%,稍低于B组98.1%,但差异无统计学意义(P<0.05);两组的月经周期、经量及痛经程度较治疗前均有显著改善(P<0.05),而A组和B组之间治疗后差异无统计学意义(P>0.05);与治疗前比较,两组子宫体积明显缩小、血CA125明显降低(P<0.05),而A组和B组之间治疗后差异无统计学意义(P>0.05),A组和B组不良反应的发生率分别为7.4%和21.2%,差异有统计学意义(P<0.05)。结论子宫腺肌病患者给予米非司酮6.25 mg.d-1治疗剂量即可取得较好的治疗效果,可减少不良反应,提高患者的耐受性。Objective To explore the clinical effect and safety of different doses of mifepristone on the treatment of uterine adenomyosis patients. Methods A hundred and six patients with uterine adenomyosis were randomly divided into two groups including group A（ n = 54 ） and group B （ n = 52 ）, which were given mifepristone for 6.25 mg · d 1 and 12.5 mg · d 1, respectively, once daily, 3 months for a course of treatment. The clinical effect, change of volume of uterus and level of CA125, and adverse effect were observed and com pared. Results After treatment, the total effective rate in group A and group B was not statistically different （94.4% vs. 98.1% ）. The menstrual cycle, menstruation and degree of dysmenorrhea in both groups were significantly improved compared with those before treatment （P 〈 0.05 ）, while there were not significant difference between group A and group B （ P 〉 0.05 ）. The volume of uterus and level of CA125 was significantly reduced compared with that before treatment（ P 〉 0.05 ）. The rate of adverse effect in group A and group B was 7.4% and 21.2%, which was significantly different （P 〈 0.05）. Conclusion The treatment doses of 6.25 mg · d 1 mifepris tone for uterine adenomyosis patients can be effective to reduce the adverse effect and improve patients＇ tolerance.

关 键 词：子宫腺肌病 米非司酮 剂量 

分 类 号：R711.71[医药卫生—妇产科学]